Fulcrum Therapeutics (FULC) FCF Margin (2020 - 2024)
Historic FCF Margin for Fulcrum Therapeutics (FULC) over the last 5 years, with Q2 2024 value amounting to 73.62%.
- Fulcrum Therapeutics' FCF Margin rose 24577100.0% to 73.62% in Q2 2024 from the same period last year, while for Mar 2025 it was 9.45%, marking a year-over-year increase of 36946300.0%. This contributed to the annual value of 3.12% for FY2024, which is 32579500.0% up from last year.
- Per Fulcrum Therapeutics' latest filing, its FCF Margin stood at 73.62% for Q2 2024, which was up 24577100.0% from 2667.62% recorded in Q4 2023.
- Over the past 5 years, Fulcrum Therapeutics' FCF Margin peaked at 73.62% during Q2 2024, and registered a low of 8232.88% during Q1 2023.
- Its 5-year average for FCF Margin is 1712.24%, with a median of 885.53% in 2022.
- In the last 5 years, Fulcrum Therapeutics' FCF Margin crashed by -73473500bps in 2023 and then surged by 24577100bps in 2024.
- Quarter analysis of 5 years shows Fulcrum Therapeutics' FCF Margin stood at 480.43% in 2020, then rose by 8bps to 442.41% in 2021, then plummeted by -554bps to 2892.26% in 2022, then grew by 8bps to 2667.62% in 2023, then soared by 103bps to 73.62% in 2024.
- Its FCF Margin stands at 73.62% for Q2 2024, versus 2667.62% for Q4 2023 and 3026.48% for Q3 2023.